Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 12(10): e0186484, 2017.
Article in English | MEDLINE | ID: mdl-29023541

ABSTRACT

We previously developed a potent candidate vaccine against bovine brucellosis caused by Brucella abortus using the influenza viral vector expressing Brucella Omp16 and L7/L12 proteins (Flu-BA). Our success in the Flu-BA vaccine trial in cattle and results of a pilot study in non-pregnant small ruminants prompted us in the current study to test its efficacy against B. melitensis infection in pregnant sheep and goats. In this study, we improved the Flu-BA vaccine formulation and immunization method to achieve maximum efficacy and safety. The Flu-BA vaccine formulation had two additional proteins Omp19 and SOD, and administered thrice with 20% Montanide Gel01 adjuvant, simultaneously by both subcutaneous and conjunctival routes at 21 days intervals in pregnant sheep and goats. At 42 days post-vaccination (DPV) we detected antigen-specific IgG antibodies predominantly of IgG2a isotype but also IgG1, and also detected a strong lymphocyte recall response with IFN-γ production. Importantly, our candidate vaccine prevented abortion in 66.7% and 77.8% of pregnant sheep and goats, respectively. Furthermore, complete protection (absence of live B. melitensis 16M) was observed in 55.6% and 66.7% of challenged sheep and goats, and 72.7% and 90.0% of their fetuses (lambs/yeanlings), respectively. The severity of B. melitensis 16M infection in vaccinated sheep and goats and their fetuses (index of infection and rates of Brucella colonization in tissues) was significantly lower than in control groups. None of the protection parameters after vaccination with Flu-BA vaccine were statistically inferior to protection seen with the commercial B. melitensis Rev.1 vaccine (protection against abortion and vaccination efficacy, alpha = 0.18-0.34, infection index, P = 0.37-0.77, Brucella colonization, P = 0.16 to P > 0.99). In conclusion, our improved Flu-BA vaccine formulation and delivery method were found safe and effective in protecting pregnant sheep and goats against adverse consequences of B. melitensis infection.


Subject(s)
B-Lymphocytes/immunology , Brucella Vaccine/immunology , Brucella melitensis/genetics , Brucellosis/prevention & control , Orthomyxoviridae/genetics , T-Lymphocytes/immunology , Abortion, Spontaneous/prevention & control , Animals , Antibodies/immunology , Antigens, Bacterial/genetics , Antigens, Bacterial/immunology , Antigens, Bacterial/metabolism , B-Lymphocytes/cytology , B-Lymphocytes/metabolism , Bacterial Outer Membrane Proteins/genetics , Bacterial Outer Membrane Proteins/immunology , Bacterial Outer Membrane Proteins/metabolism , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Bacterial Proteins/metabolism , Brucella Vaccine/genetics , Brucella Vaccine/metabolism , Brucella melitensis/pathogenicity , Brucellosis/immunology , Female , Goats , Hemagglutinins, Viral/immunology , Immunoglobulin G/immunology , Interferon-gamma/metabolism , Lipoproteins/genetics , Lipoproteins/immunology , Lipoproteins/metabolism , Pregnancy , Sheep , Superoxide Dismutase-1/genetics , Superoxide Dismutase-1/immunology , Superoxide Dismutase-1/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/metabolism , Vaccination
2.
J Vet Med Sci ; 78(10): 1541-1548, 2016 Nov 01.
Article in English | MEDLINE | ID: mdl-27349900

ABSTRACT

Brucella abortus cells were lysed by the N-terminal 24-amino acid fragment (GI24) of the 36-amino acid peptide PMAP-36 (porcine myeloid antimicrobial peptide 36). Next, the protection efficacy of the lysed fragment as a vaccine candidate was evaluated. Group A mice were immunized with sterile PBS, group B mice were intraperitoneally (ip) immunized with 3 × 108 colony-forming units (CFUs) of B. abortus strain RB51, group C mice were immunized ip with 3 × 108 cells of the B. abortus vaccine candidate, and group D mice were orally immunized with 3 × 109 cells of the B. abortus vaccine candidate. Brucella lipopolysaccharide (LPS)-specific serum IgG titers were considerably higher in groups C and D than in group A. The levels of interleukin (IL)-4, IL-10, tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) were significantly higher in groups B-D than in group A. After an ip challenge with B. abortus 544, only group C mice showed a significant level of protection as compared to group A. Overall, these results show that ip immunization with a vaccine candidate lysed by GI24 can effectively protect mice from systemic infection with virulent B. abortus.


Subject(s)
Brucella Vaccine/immunology , Brucella abortus/immunology , Brucellosis/prevention & control , Proteins/metabolism , Animals , Antimicrobial Cationic Peptides , Brucella Vaccine/metabolism , Brucella abortus/metabolism , Cytokines/metabolism , Disease Models, Animal , Immunity, Cellular , Immunity, Humoral , Mice , Mice, Inbred BALB C , Peptide Fragments/metabolism , Swine
3.
Indian J Exp Biol ; 43(9): 838-40, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16187538

ABSTRACT

Brucella melitensis is an organism of paramount zoonotic importance. The 28 kDa outer membrane protein (OMP) is one of the immunodominant antigens of B. melitensis. The gene encoding 28 kDa OMP (omp28) has been amplified from B. melitensis Rev. 1 strain. A PCR product of 753 bp, encoding complete omp28 gene of B. melitensis, was obtained. The gene was further cloned and sequenced. The nucleotide sequence of B. melitensis Rev. 1 strain showed substitution of 2 nucleotides from that of 16M strain.


Subject(s)
Brucella melitensis/metabolism , Antigens, Bacterial , Bacterial Outer Membrane Proteins/metabolism , Base Sequence , Brucella Vaccine/metabolism , Cell Membrane/metabolism , Cloning, Molecular , Molecular Sequence Data , Plasmids/metabolism , Polymerase Chain Reaction , Protein Structure, Tertiary , Recombinant Proteins/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...